152121-32-9

Upstream product

• 301836-29-3 4-[4-(4-fluorophenyl)-5-(2-pyridyl)-1H-imidazol-2-yl]benzonitrile 
• 7732-18-5 water 
• 152121-19-2 2-(4-Cyanophenyl)-4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazole 

Downstream Products

• 172747-43-2 ethyl 4-[4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl]-benzoate 

Relevant academic research and scientific papers

Triarylimidazoles

Compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R2and R3are various substituent groups; and one of X1and X2is N or CR′, and the other is NR′ or CHR′ wherein R′ is hydrogen, OH, C1-6alkyl, or C3-7cycloalkyl; or when one of X1and X2is N or CR′ then the other may be S or O; and their use as pharmaceuticals.

Treatment for CNS injuries

The present invention is directed to the use of 2,4,5-trisubstituted imidazole compounds and compositions in the treatment of CNS injuries to the brain.

Use of kinase inhibitors for treating neurodegenerative diseases

The present invention relates to methods of treating neurodegenerative diseases, including but not limited to Parkinson's disease. In particular, the present invention provides methods utilizing the administration of pyridyl imidazoles having simultaneous inhibitory activity towards p38 mitogen-activated protein (MAP) kinase and c-jun-N-terminal kinase (JNK). The present invention also provides methods for preventing apoptosis of dopamine neurons using pyridyl imidazoles. The present invention also provides methods for the treatment of neurodegenerative diseases, including but not limited to Parkinson's disease.

Pyrimidinyl imidazoles

Novel 2,4,5-triaryl imidazole compounds and compositions for use in therapy.

Pyridyl imidazoles

Novel 2,4,5-triaryl imidazole compounds and compositions for use in therapy.

Imidazole derivatives and their use as cytokine inhibitors

As cytokine inhibitors 2,4,5-triarylimidazole compounds and compositions for use as cytokine inhibitors.